Inclusion Criteria:

• • Body mass index (BMI) and body weight of subjects: 15.0≤BMI≤28.0 kg/m2, and 40kg≤ body weight ≤90kg;

  • For clinically diagnosed patients with tuberculosis whose drug sensitivity test has proved to be at least resistant to rifampicin, phenotypic or molecular drug sensitivity test results within 3 months before the subject signs informed consent can be accepted;
  • Direct sputum smear positive for acid-fast bacilli (AFB at least 1+);
  • Willing to discontinue all previous anti-tuberculosis drugs and accept a 7-day washout period;
  • Non-lactating and pregnant women who agree to use contraception throughout the treatment; Or the male patient's spouse agrees to use contraception throughout the treatment.

Exclusion Criteria:

• • Allergic to any study drug or its ingredients;

  • A history of alcohol dependence or drug abuse;
  • With hematogenous disseminated pulmonary tuberculosis or extrapulmonary tuberculosis;
  • Drug susceptibility test before screening showed resistance to more than 4 of the 8 antituberculosis drugs in this study;
  • Have taken Bedaquiline before;
  • HIV-positive patients;
  • Laboratory obvious abnormalities;
  • A history of pointy torsion ventricular tachycardia or cardiac risk factors for pointy torsion ventricular tachycardia;
  • Repeated QTcF intervals > 450ms; Clinically significant ventricular arrhythmias that may require medical or surgical treatment;
  • Documented cardiovascular diseases;
  • Peripheral neuropathy CTCAE grade 3 or grade 4; Grade 1 or grade 2 neuropathy that the investigator believes is likely to progress/worsen over the course of the study; optic neuritis;
  • Any serious cardiovascular, kidney, liver, blood, tumor, endocrine and metabolic, autoimmune or rheumatic diseases.